At the American Heart Association conference yesterday a new study was released that showed that Pfizer’s cholesterol drug Lipitor, showed no significant reduction in “major coronary events” versus rival treatment Merck’s Zocor.
The five-year study found no statistically significant difference between Lipitor and US drugmaker Merck’s Zocor in reducing heart disease-related death, heart attack and cardiac arrest. Results of the study were presented on Tuesday at an American Heart Association conference.
The study did show a difference in some secondary targets. Lipitor was 13 per cent better than Zocor in reducing major heart events when strokes were included.
The comparison between Lipitor and Zocor is important for Pfizer. The world’s largest drugmaker continuously seeks to develop an extensive body of data that will persuade doctors that Lipitor, the biggest-selling drug in the world with $12 billion, yes that is Billion dollars in sales this year, is better than older, cheaper drugs from the same statin class of cholesterol reducers. Pfizer wants to preserve sales in the face of generic versions of Zocor, whose US patent expires next year.
Read the rest of this entry »
Looking to make a change and lose some weight? I have reviewed the top diet on the internet and you can go and read over 200 comments people have made about why this diet has worked well for them, as well as some of the problems.
Tags: American Heart Association, cardiac arrest, heart attack, heart attacks, heart disease, lipitor, Merck, pfizer, United States, USD, Zocor













































Entries (RSS)